Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $25

Benzinga Newsdesk www.benzinga.com Negative 49.4%

Neg 49.4% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight and lowers the price target from $27 to $25.